Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial

This study analyzed the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes. This study was a posttrial follow-up of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial. Participants in the JPAD trial (2,536 Japanese patients with ty...

Full description

Saved in:
Bibliographic Details
Published inDiabetes care Vol. 41; no. 8; pp. 1757 - 1764
Main Authors Okada, Sadanori, Morimoto, Takeshi, Ogawa, Hisao, Sakuma, Mio, Matsumoto, Chisa, Soejima, Hirofumi, Nakayama, Masafumi, Doi, Naofumi, Jinnouchi, Hideaki, Waki, Masako, Masuda, Izuru, Saito, Yoshihiko
Format Journal Article
LanguageEnglish
Published United States American Diabetes Association 01.08.2018
Subjects
Adult
Aged
Aged, 80 and over
Arteriosclerosis
Aspirin
Aspirin - therapeutic use
Atherosclerosis
Cancer
Cardiovascular diseases
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - prevention & control
Chemoprevention - methods
Chemotherapy
Clinical trials
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - epidemiology
Evidence-based medicine
Female
Follow-Up Studies
Hemoglobin
Humans
Incidence
Japan - epidemiology
Male
Metformin
Metformin - therapeutic use
Middle Aged
Neoplasms - epidemiology
Neoplasms - prevention & control
Patients
Research design
Smoking
Statins
Subgroups
Online AccessGet full text

Cover

Abstract This study analyzed the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes. This study was a posttrial follow-up of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial. Participants in the JPAD trial (2,536 Japanese patients with type 2 diabetes and without preexisting cardiovascular disease) were randomly allocated to receive aspirin (81 or 100 mg daily) or no aspirin. After that trial ended in 2008, we followed up with the participants until 2015, with no attempt to change the previously assigned therapy. The primary end point was total cancer incidence. We investigated the effect of low-dose aspirin on cancer incidence. During the median follow-up period of 10.7 years, a total of 318 cancers occurred. The cancer incidence was not significantly different between the aspirin and no-aspirin groups (log-rank, = 0.4; hazard ratio [HR], 0.92; 95% CI, 0.73-1.14; = 0.4). In subgroup analyses, aspirin did not affect cancer incidence in men, women, or participants aged ≥65 years. However, it decreased cancer incidence in participants aged <65 years (log-rank, = 0.05; HR, 0.67; 95% CI, 0.44-0.99; = 0.048). After adjusting for sex, hemoglobin A , smoking status, and administration of metformin and statins, aspirin significantly reduced cancer incidence in participants aged <65 years (adjusted HR, 0.66; 95% CI, 0.43-0.99; = 0.04). Low-dose aspirin did not reduce cancer incidence in Japanese patients with type 2 diabetes.
AbstractList OBJECTIVE This study analyzed the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes. RESEARCH DESIGN AND METHODS This study was a posttrial follow-up of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial. Participants in the JPAD trial (2,536 Japanese patients with type 2 diabetes and without preexisting cardiovascular disease) were randomly allocated to receive aspirin (81 or 100 mg daily) or no aspirin. After that trial ended in 2008, we followed up with the participants until 2015, with no attempt to change the previously assigned therapy. The primary end point was total cancer incidence. We investigated the effect of low-dose aspirin on cancer incidence. RESULTS During the median follow-up period of 10.7 years, a total of 318 cancers occurred. The cancer incidence was not significantly different between the aspirin and no-aspirin groups (log-rank, P = 0.4; hazard ratio [HR], 0.92; 95% CI, 0.73–1.14; P = 0.4). In subgroup analyses, aspirin did not affect cancer incidence in men, women, or participants aged ≥65 years. However, it decreased cancer incidence in participants aged <65 years (log-rank, P = 0.05; HR, 0.67; 95% CI, 0.44–0.99; P = 0.048). After adjusting for sex, hemoglobin A1c, smoking status, and administration of metformin and statins, aspirin significantly reduced cancer incidence in participants aged <65 years (adjusted HR, 0.66; 95% CI, 0.43–0.99; P = 0.04). CONCLUSIONS Low-dose aspirin did not reduce cancer incidence in Japanese patients with type 2 diabetes.
OBJECTIVE This study analyzed the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes. RESEARCH DESIGN AND METHODS This study was a posttrial follow-up of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial. Participants in the JPAD trial (2,536 Japanese patients with type 2 diabetes and without preexisting cardiovascular disease) were randomly allocated to receive aspirin (81 or 100 mg daily) or no aspirin. After that trial ended in 2008, we followed up with the participants until 2015, with no attempt to change the previously assigned therapy. The primary end point was total cancer incidence. We investigated the effect of low-dose aspirin on cancer incidence. RESULTS During the median follow-up period of 10.7 years, a total of 318 cancers occurred. The cancer incidence was not significantly different between the aspirin and no-aspirin groups (log-rank, P = 0.4; hazard ratio [HR], 0.92; 95% CI, 0.73–1.14; P = 0.4). In subgroup analyses, aspirin did not affect cancer incidence in men, women, or participants aged ≥65 years. However, it decreased cancer incidence in participants aged <65 years (log-rank, P = 0.05; HR, 0.67; 95% CI, 0.44–0.99; P = 0.048). After adjusting for sex, hemoglobin A1c, smoking status, and administration of metformin and statins, aspirin significantly reduced cancer incidence in participants aged <65 years (adjusted HR, 0.66; 95% CI, 0.43–0.99; P = 0.04). CONCLUSIONS Low-dose aspirin did not reduce cancer incidence in Japanese patients with type 2 diabetes.
OBJECTIVEThis study analyzed the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes.RESEARCH DESIGN AND METHODSThis study was a posttrial follow-up of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial. Participants in the JPAD trial (2,536 Japanese patients with type 2 diabetes and without preexisting cardiovascular disease) were randomly allocated to receive aspirin (81 or 100 mg daily) or no aspirin. After that trial ended in 2008, we followed up with the participants until 2015, with no attempt to change the previously assigned therapy. The primary end point was total cancer incidence. We investigated the effect of low-dose aspirin on cancer incidence.RESULTSDuring the median follow-up period of 10.7 years, a total of 318 cancers occurred. The cancer incidence was not significantly different between the aspirin and no-aspirin groups (log-rank, P = 0.4; hazard ratio [HR], 0.92; 95% CI, 0.73-1.14; P = 0.4). In subgroup analyses, aspirin did not affect cancer incidence in men, women, or participants aged ≥65 years. However, it decreased cancer incidence in participants aged <65 years (log-rank, P = 0.05; HR, 0.67; 95% CI, 0.44-0.99; P = 0.048). After adjusting for sex, hemoglobin A1c, smoking status, and administration of metformin and statins, aspirin significantly reduced cancer incidence in participants aged <65 years (adjusted HR, 0.66; 95% CI, 0.43-0.99; P = 0.04).CONCLUSIONSLow-dose aspirin did not reduce cancer incidence in Japanese patients with type 2 diabetes.
This study analyzed the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes. This study was a posttrial follow-up of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial. Participants in the JPAD trial (2,536 Japanese patients with type 2 diabetes and without preexisting cardiovascular disease) were randomly allocated to receive aspirin (81 or 100 mg daily) or no aspirin. After that trial ended in 2008, we followed up with the participants until 2015, with no attempt to change the previously assigned therapy. The primary end point was total cancer incidence. We investigated the effect of low-dose aspirin on cancer incidence. During the median follow-up period of 10.7 years, a total of 318 cancers occurred. The cancer incidence was not significantly different between the aspirin and no-aspirin groups (log-rank, = 0.4; hazard ratio [HR], 0.92; 95% CI, 0.73-1.14; = 0.4). In subgroup analyses, aspirin did not affect cancer incidence in men, women, or participants aged ≥65 years. However, it decreased cancer incidence in participants aged <65 years (log-rank, = 0.05; HR, 0.67; 95% CI, 0.44-0.99; = 0.048). After adjusting for sex, hemoglobin A , smoking status, and administration of metformin and statins, aspirin significantly reduced cancer incidence in participants aged <65 years (adjusted HR, 0.66; 95% CI, 0.43-0.99; = 0.04). Low-dose aspirin did not reduce cancer incidence in Japanese patients with type 2 diabetes.
Author Jinnouchi, Hideaki
Sakuma, Mio
Matsumoto, Chisa
Waki, Masako
Morimoto, Takeshi
Ogawa, Hisao
Saito, Yoshihiko
Okada, Sadanori
Doi, Naofumi
Nakayama, Masafumi
Masuda, Izuru
Soejima, Hirofumi
Author_xml – sequence: 1
  givenname: Sadanori
  surname: Okada
  fullname: Okada, Sadanori
– sequence: 2
  givenname: Takeshi
  surname: Morimoto
  fullname: Morimoto, Takeshi
– sequence: 3
  givenname: Hisao
  surname: Ogawa
  fullname: Ogawa, Hisao
– sequence: 4
  givenname: Mio
  surname: Sakuma
  fullname: Sakuma, Mio
– sequence: 5
  givenname: Chisa
  surname: Matsumoto
  fullname: Matsumoto, Chisa
– sequence: 6
  givenname: Hirofumi
  orcidid: 0000-0002-7520-2008
  surname: Soejima
  fullname: Soejima, Hirofumi
– sequence: 7
  givenname: Masafumi
  surname: Nakayama
  fullname: Nakayama, Masafumi
– sequence: 8
  givenname: Naofumi
  surname: Doi
  fullname: Doi, Naofumi
– sequence: 9
  givenname: Hideaki
  surname: Jinnouchi
  fullname: Jinnouchi, Hideaki
– sequence: 10
  givenname: Masako
  surname: Waki
  fullname: Waki, Masako
– sequence: 11
  givenname: Izuru
  surname: Masuda
  fullname: Masuda, Izuru
– sequence: 12
  givenname: Yoshihiko
  orcidid: 0000-0001-5574-3571
  surname: Saito
  fullname: Saito, Yoshihiko
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29909377$$D View this record in MEDLINE/PubMed
BookMark eNpdkc1q3TAQhUVISG5us8gLFEE37cKpZMm21F1w89MSSCkXSldmbI-Igi25kp2QvkhfNzJJu-hqhplvZjhzjsm-8w4JOeXsLBei-th3XGVMlGqPbLgWRVYUUu2TDeNSZ4XW-RE5jvGeMSalUofkKNeaaVFVG_LnwhjsZuoNPY-TDdZR72gNrsNA6zsc_RTwAd1sUzk1v8IEDiPSbzDbVI70h53v6O5pQprTzxZanDF-opxlPxECvW0jhgdYx2Ggl34Y_GO2TOs9oN_B9X60v7GntXdzSN2U7oKF4Q05MDBEPHmNW7K7vNjV19nN7dWX-vwm64RUc2aMkR1Ax6XUuQDGVF5hwVQhjZJGc1m2ZVVqJbHVEvskX5a5QjCFAsmZ2JL3L2un4H8tGOdmtLHDYUgi_RKbnBVpnjNeJfTdf-i9X0JSlagECKHL9Pst-fBCdcHHGNA0U7AjhKeGs2Y1q1nNalazEvv2dePSjtj_I_-6I54BK-yQNg
CitedBy_id crossref_primary_10_3390_ijms21249585
crossref_primary_10_1001_jama_2024_4840
crossref_primary_10_1016_j_bcp_2020_113895
crossref_primary_10_1007_s00432_019_02932_0
crossref_primary_10_1001_jama_2018_20578
crossref_primary_10_3390_cancers14051211
crossref_primary_10_1007_s10555_018_9755_8
crossref_primary_10_1007_s11606_020_06167_5
crossref_primary_10_1007_s00432_019_02902_6
crossref_primary_10_1111_joim_13590
crossref_primary_10_1007_s00432_019_03069_w
crossref_primary_10_1158_1940_6207_CAPR_22_0087
crossref_primary_10_3390_cancers11101468
crossref_primary_10_3892_etm_2021_10875
crossref_primary_10_1111_jgh_14562
crossref_primary_10_1001_jama_2022_3337
Cites_doi 10.1111/jdi.12645
10.1093/jnci/djv009
10.1056/NEJMoa1008862
10.7326/0003-4819-159-2-201307160-00002
10.1093/jnci/dji375
10.1001/jama.1995.03520440059037
10.1158/0008-5472.CAN-07-2310
10.1677/ERC-09-0087
10.1093/eurheartj/eht108
10.1056/NEJM199112053252301
10.7326/M15-2129
10.1016/S0140-6736(10)61543-7
10.1007/s13340-013-0121-3
10.1016/S0140-6736(10)62110-1
10.1093/jnci/dji173
10.1002/ijc.29813
10.1001/jama.295.1.74
10.1001/jama.2008.623
10.1111/cas.12241
10.4158/EP10357.RA
10.1038/bjc.2016.149
10.1016/S0140-6736(09)60503-1
10.1136/bmj.i6188
10.1161/CIRCULATIONAHA.116.025760
10.1158/1055-9965.EPI-06-0410
10.1016/j.ejca.2008.06.025
10.1016/j.jdiacomp.2010.06.004
10.7326/M16-0577
10.2337/dc08-1034
10.2337/dc10-0666
10.1007/s00125-006-0468-0
10.2337/dc10-0555
10.1093/jnci/djn485
10.1016/S0140-6736(11)61049-0
10.1093/annonc/mdw410
10.1016/S0140-6736(11)61720-0
ContentType Journal Article
Contributor Hokamaki, Jun
Fukami, Ryo
Ogihara, Masayuki
Soeda, Tsunenari
Okada, Koichi
Sawada, Tomohiro
Maki, Akira
Tokube, Koji
Sawai, Koryo
Ueda, Tomoya
Yokota, Hiromitsu
Fujiki, Kengo
Yamada, Hideki
Ono, Takashi
Fukuoka, Yoshiaki
Marutsuka, Kousuke
Kajiwara, Keizo
Kiyota, Mayumi
Iwai, Ken
Hayashi, Motomu
Yoshimoto, Kazumi
Tomioka, Yukio
Misugi, Susumu
Yazaki, Akihiro
Naito, Masaki
Kinoshita, Yoshimi
Shimono, Hisashi
Yamaga, Kenichi
Hiramori, Yuko
Doi, Osamu
Ohsumi, Kyouyuki
Minoda, Kotaro
Kondo, Norifumi
Tanazawa, Satoshi
Kudou, Kiyotaka
Fujii, Yoshihiro
Kagoshima, Tadashi
Ozaki, Ken
Kawamura, Kyousuke
Koga, Takeshi
Nakano, Yukitaka
Kuwahara, Tetsuo
Matsuo, Syuichi
Minami, Shigetoshi
Shiiki, Hideo
Yabuta, Matahiro
Obata, Kenji
Doijiri, Kenichi
Horie, Hiroaki
Iwama, Hajime
Akahoshi, Kazunobu
Yamada, Kazuhiko
Sugimoto, Keisuke
Morikami, Yasuhiro
Ozawa, Seiji
Ishibashi, Yutaka
Hamano, Masayoshi
Takaoka, Kyoji
Hasegawa, Hiromi
Hifumi, Atuko
Taguchi, Madoka
Fukuda, Masahiro
Sakan, Hirokazu
Sutani, Toshio
Kimura, Yoshihiro
Goshi, Kazuto
Sawada, Yoko
Tomita, Fumishi
T
Contributor_xml – sequence: 2
  givenname: Kazunobu
  surname: Akahoshi
  fullname: Akahoshi, Kazunobu
– sequence: 3
  givenname: Kenji
  surname: Misumi
  fullname: Misumi, Kenji
– sequence: 4
  givenname: Haruo
  surname: Araki
  fullname: Araki, Haruo
– sequence: 7
  givenname: Kenichi
  surname: Ashihara
  fullname: Ashihara, Kenichi
– sequence: 8
  givenname: Shinya
  surname: Yumoto
  fullname: Yumoto, Shinya
– sequence: 9
  givenname: Masashi
  surname: Horimoto
  fullname: Horimoto, Masashi
– sequence: 10
  givenname: Osamu
  surname: Doi
  fullname: Doi, Osamu
– sequence: 13
  givenname: Michio
  surname: Shimabukuro
  fullname: Shimabukuro, Michio
– sequence: 14
  givenname: Genshi
  surname: Egusa
  fullname: Egusa, Genshi
– sequence: 16
  givenname: Yoichi
  surname: Hanaoka
  fullname: Hanaoka, Yoichi
– sequence: 20
  givenname: Atsushi
  surname: Hasegawa
  fullname: Hasegawa, Atsushi
– sequence: 21
  givenname: Yoshiko
  surname: Shioya
  fullname: Shioya, Yoshiko
– sequence: 22
  givenname: Yosuke
  surname: Shioya
  fullname: Shioya, Yosuke
– sequence: 27
  givenname: Yutaka
  surname: Horio
  fullname: Horio, Yutaka
– sequence: 28
  givenname: Seishi
  surname: Ichihara
  fullname: Ichihara, Seishi
– sequence: 31
  givenname: Makoto
  surname: Ikemura
  fullname: Ikemura, Makoto
– sequence: 37
  givenname: Masanori
  surname: Kamura
  fullname: Kamura, Masanori
– sequence: 39
  givenname: Mayumi
  surname: Kiyota
  fullname: Kiyota, Mayumi
– sequence: 45
  givenname: Kazuo
  surname: Kozuma
  fullname: Kozuma, Kazuo
– sequence: 46
  givenname: Kiyotaka
  surname: Kudou
  fullname: Kudou, Kiyotaka
– sequence: 50
  givenname: Hisao
  surname: Fujimoto
  fullname: Fujimoto, Hisao
– sequence: 51
  givenname: Kozaburo
  surname: Matsuyama
  fullname: Matsuyama, Kozaburo
– sequence: 56
  givenname: Kazuo
  surname: Machii
  fullname: Machii, Kazuo
– sequence: 58
  givenname: Keiji
  surname: Mahara
  fullname: Mahara, Keiji
– sequence: 60
  givenname: Naoki
  surname: Manda
  fullname: Manda, Naoki
– sequence: 61
  givenname: Kousuke
  surname: Marutsuka
  fullname: Marutsuka, Kousuke
– sequence: 66
  givenname: Hiroto
  surname: Okubo
  fullname: Okubo, Hiroto
– sequence: 67
  givenname: Fuyuki
  surname: Minagawa
  fullname: Minagawa, Fuyuki
– sequence: 68
  givenname: Kotaro
  surname: Minoda
  fullname: Minoda, Kotaro
– sequence: 74
  givenname: Hisatoshi
  surname: Nagano
  fullname: Nagano, Hisatoshi
– sequence: 75
  givenname: Kazuto
  surname: Goshi
  fullname: Goshi, Kazuto
– sequence: 79
  givenname: Hiroyuki
  surname: Tanaka
  fullname: Tanaka, Hiroyuki
– sequence: 80
  givenname: Ryuji
  surname: Sonoda
  fullname: Sonoda, Ryuji
– sequence: 81
  givenname: Keizo
  surname: Kajiwara
  fullname: Kajiwara, Keizo
– sequence: 82
  givenname: Takafumi
  surname: Odo
  fullname: Odo, Takafumi
– sequence: 83
  givenname: Hirofumi
  surname: Ogata
  fullname: Ogata, Hirofumi
– sequence: 84
  givenname: Masayuki
  surname: Ogihara
  fullname: Ogihara, Masayuki
– sequence: 85
  givenname: Tateo
  surname: Ogura
  fullname: Ogura, Tateo
– sequence: 86
  givenname: Keishiro
  surname: Oka
  fullname: Oka, Keishiro
– sequence: 87
  givenname: Eiji
  surname: Kawashima
  fullname: Kawashima, Eiji
– sequence: 89
  givenname: Ken
  surname: Ozaki
  fullname: Ozaki, Ken
– sequence: 90
  givenname: Seiji
  surname: Ozawa
  fullname: Ozawa, Seiji
– sequence: 95
  givenname: Tomohiro
  surname: Sawada
  fullname: Sawada, Tomohiro
– sequence: 96
  givenname: Junji
  surname: Shibata
  fullname: Shibata, Junji
– sequence: 97
  givenname: Hisashi
  surname: Shimono
  fullname: Shimono, Hisashi
– sequence: 99
  givenname: Akira
  surname: Matsutani
  fullname: Matsutani, Akira
– sequence: 100
  givenname: Hisakazu
  surname: Suefuji
  fullname: Suefuji, Hisakazu
– sequence: 108
  givenname: Koryo
  surname: Sawai
  fullname: Sawai, Koryo
– sequence: 112
  givenname: Koji
  surname: Tokube
  fullname: Tokube, Koji
– sequence: 118
  givenname: Kaoru
  surname: Tsuda
  fullname: Tsuda, Kaoru
– sequence: 120
  givenname: Kenji
  surname: Obata
  fullname: Obata, Kenji
– sequence: 121
  givenname: Katumi
  surname: Watanabe
  fullname: Watanabe, Katumi
– sequence: 123
  givenname: Yutaka
  surname: Ishibashi
  fullname: Ishibashi, Yutaka
– sequence: 125
  givenname: Yoshito
  surname: Yamanaka
  fullname: Yamanaka, Yoshito
– sequence: 126
  givenname: Kazuhiro
  surname: Sonoda
  fullname: Sonoda, Kazuhiro
– sequence: 127
  givenname: Taisuke
  surname: Iwaoka
  fullname: Iwaoka, Taisuke
– sequence: 131
  givenname: Noriaki
  surname: Ando
  fullname: Ando, Noriaki
– sequence: 132
  givenname: Hiroshi
  surname: Bando
  fullname: Bando, Hiroshi
– sequence: 133
  givenname: Takeshi
  surname: Takami
  fullname: Takami, Takeshi
– sequence: 134
  givenname: Michiaki
  surname: Doi
  fullname: Doi, Michiaki
– sequence: 135
  givenname: Yoshihiro
  surname: Fujii
  fullname: Fujii, Yoshihiro
– sequence: 136
  givenname: Masahiro
  surname: Fukuda
  fullname: Fukuda, Masahiro
– sequence: 137
  givenname: Yoshiaki
  surname: Fukuoka
  fullname: Fukuoka, Yoshiaki
– sequence: 140
  givenname: Hiromi
  surname: Hasegawa
  fullname: Hasegawa, Hiromi
– sequence: 142
  givenname: Kenshi
  surname: Higami
  fullname: Higami, Kenshi
– sequence: 143
  givenname: Satomi
  surname: Higami
  fullname: Higami, Satomi
– sequence: 144
  givenname: Akiko
  surname: Yasuno
  fullname: Yasuno, Akiko
– sequence: 146
  givenname: Yoko
  surname: Onishi
  fullname: Onishi, Yoko
– sequence: 148
  givenname: Shigetoshi
  surname: Minami
  fullname: Minami, Shigetoshi
– sequence: 149
  givenname: Takao
  surname: Nakashima
  fullname: Nakashima, Takao
– sequence: 150
  givenname: Hiroaki
  surname: Horie
  fullname: Horie, Hiroaki
– sequence: 151
  givenname: Kazuko
  surname: Horii
  fullname: Horii, Kazuko
– sequence: 152
  givenname: Norihiko
  surname: Matsumura
  fullname: Matsumura, Norihiko
– sequence: 161
  givenname: Hisaharu
  surname: Makino
  fullname: Makino, Hisaharu
– sequence: 162
  givenname: Hiroshi
  surname: Miki
  fullname: Miki, Hiroshi
– sequence: 167
  givenname: Akira
  surname: Nakatani
  fullname: Nakatani, Akira
– sequence: 172
  givenname: Hiroyuki
  surname: Kawata
  fullname: Kawata, Hiroyuki
– sequence: 173
  givenname: Kenichi
  surname: Samejima
  fullname: Samejima, Kenichi
– sequence: 174
  givenname: Kenji
  surname: Onoue
  fullname: Onoue, Kenji
– sequence: 175
  givenname: Rika
  surname: Kawakami
  fullname: Kawakami, Rika
– sequence: 176
  givenname: Tomoya
  surname: Nakano
  fullname: Nakano, Tomoya
– sequence: 180
  givenname: Fumitaka
  surname: Inoue
  fullname: Inoue, Fumitaka
– sequence: 181
  givenname: Shigeru
  surname: Yamano
  fullname: Yamano, Shigeru
– sequence: 184
  givenname: Megumi
  surname: Suzuki
  fullname: Suzuki, Megumi
– sequence: 186
  givenname: Takehito
  surname: Nakai
  fullname: Nakai, Takehito
– sequence: 194
  givenname: Takahiro
  surname: Kawano
  fullname: Kawano, Takahiro
– sequence: 195
  givenname: Hideki
  surname: Yamada
  fullname: Yamada, Hideki
– sequence: 197
  givenname: Kyouyuki
  surname: Ohsumi
  fullname: Ohsumi, Kyouyuki
– sequence: 198
  givenname: Nobushige
  surname: Ote
  fullname: Ote, Nobushige
– sequence: 205
  givenname: Yoko
  surname: Sawada
  fullname: Sawada, Yoko
– sequence: 209
  givenname: Toshio
  surname: Sutani
  fullname: Sutani, Toshio
– sequence: 210
  givenname: Yuko
  surname: Hiramori
  fullname: Hiramori, Yuko
– sequence: 211
  givenname: Yuya
  surname: Tanaka
  fullname: Tanaka, Yuya
– sequence: 215
  givenname: Kiyotaka
  surname: Sugihara
  fullname: Sugihara, Kiyotaka
– sequence: 216
  givenname: Motomu
  surname: Hayashi
  fullname: Hayashi, Motomu
– sequence: 217
  givenname: Yasunobu
  surname: Sasaki
  fullname: Sasaki, Yasunobu
– sequence: 218
  givenname: Yasuo
  surname: Matsukura
  fullname: Matsukura, Yasuo
– sequence: 220
  givenname: Masakuni
  surname: Ueyama
  fullname: Ueyama, Masakuni
– sequence: 223
  givenname: Kenichi
  surname: Yamaga
  fullname: Yamaga, Kenichi
– sequence: 226
  givenname: Midori
  surname: Yoshimura
  fullname: Yoshimura, Midori
Copyright 2018 by the American Diabetes Association.
Copyright American Diabetes Association Aug 1, 2018
Copyright_xml – notice: 2018 by the American Diabetes Association.
– notice: Copyright American Diabetes Association Aug 1, 2018
CorporateAuthor JPAD Trial Investigators
CorporateAuthor_xml – name: JPAD Trial Investigators
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
K9.
NAPCQ
7X8
DOI 10.2337/dc18-0368
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
CrossRef
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1935-5548
EndPage 1764
ExternalDocumentID 10_2337_dc18_0368
29909377
Genre Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
Observational Study
GroupedDBID ---
-ET
..I
.55
.GJ
.XZ
08P
0R~
18M
29F
2WC
3O-
3V.
4.4
41~
53G
5GY
5RE
5RS
5VS
6PF
7RV
7X2
7X7
88E
88I
8AF
8AO
8C1
8F7
8FE
8FH
8FI
8FJ
8G5
8R4
8R5
AAIKC
AAKAS
AAMNW
AAQOH
AAQQT
AAWTL
AAYEP
AAYJJ
ABOCM
ABPPZ
ABUWG
ACGFO
ACGOD
ADBBV
ADZCM
AEGXH
AENEX
AERZD
AFDAS
AFFNX
AFKRA
AFOSN
AFRAH
AHMBA
AI.
AIAGR
ALMA_UNASSIGNED_HOLDINGS
AN0
AQUVI
ATCPS
AZQEC
BAWUL
BCR
BCU
BEC
BENPR
BHPHI
BKEYQ
BKNYI
BLC
BNQBC
BPHCQ
BTFSW
BVXVI
C1A
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
DWQXO
E3Z
EBS
ECM
EDB
EIF
EJD
EMOBN
EX3
F5P
FYUFA
GNUQQ
GUQSH
GX1
HCIFZ
HMCUK
HZ~
IAG
IAO
IEA
IGG
IHR
INH
INR
IOF
IPO
ITC
J5H
K9-
KQ8
L7B
M0K
M0R
M0T
M1P
M2O
M2P
M2Q
M5~
N4W
NAPCQ
NPM
O5R
O5S
O9-
OK1
OVD
P2P
PCD
PEA
PQQKQ
PROAC
PSQYO
Q2X
RHF
RHI
S0X
SJFOW
SV3
TDI
TEORI
TR2
TWZ
UKHRP
VH1
VVN
W8F
WH7
WHG
WOQ
WOW
X7M
YHG
YOC
ZA5
ZCG
ZGI
ZXP
~KM
AAYXX
ALIPV
CITATION
H13
K9.
7X8
ID FETCH-LOGICAL-c348t-fff4caac144923a00827e50854f84f9146b676984eb94ed4484628eaf58a4103
ISSN 0149-5992
IngestDate Wed Jul 17 03:13:59 EDT 2024
Sat Aug 31 00:10:24 EDT 2024
Fri Aug 23 01:28:02 EDT 2024
Fri May 24 00:05:29 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License 2018 by the American Diabetes Association.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c348t-fff4caac144923a00827e50854f84f9146b676984eb94ed4484628eaf58a4103
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-3
ObjectType-Feature-4
content type line 23
ObjectType-Undefined-2
ORCID 0000-0001-5574-3571
0000-0002-7520-2008
OpenAccessLink https://care.diabetesjournals.org/content/diacare/41/8/1757.full.pdf
PMID 29909377
PQID 2101339619
PQPubID 47715
PageCount 8
ParticipantIDs proquest_miscellaneous_2056761017
proquest_journals_2101339619
crossref_primary_10_2337_dc18_0368
pubmed_primary_29909377
PublicationCentury 2000
PublicationDate 2018-08-00
2018-08-01
20180801
PublicationDateYYYYMMDD 2018-08-01
PublicationDate_xml – month: 08
  year: 2018
  text: 2018-08-00
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Alexandria
PublicationTitle Diabetes care
PublicationTitleAlternate Diabetes Care
PublicationYear 2018
Publisher American Diabetes Association
Publisher_xml – name: American Diabetes Association
References Kuoppala (2022031300590168400_B36) 2008; 44
Kasuga (2022031300590168400_B9) 2013; 4
Coyle (2022031300590168400_B23) 2016; 27
Everhart (2022031300590168400_B3) 1995; 273
Ogawa (2022031300590168400_B20) 2008; 300
Burn (2022031300590168400_B17) 2011; 378
Vigneri (2022031300590168400_B30) 2009; 16
Dowling (2022031300590168400_B34) 2007; 67
Rao Kondapally Seshasai (2022031300590168400_B10) 2011; 364
2022031300590168400_B31
Cook (2022031300590168400_B22) 2013; 159
Rothwell (2022031300590168400_B15) 2011; 377
Mitri (2022031300590168400_B6) 2008; 31
Noto (2022031300590168400_B7) 2011; 17
Pignone (2022031300590168400_B26) 2010; 33
Noto (2022031300590168400_B8) 2010; 24
Wang (2022031300590168400_B24) 2016; 115
Saito (2022031300590168400_B21) 2017; 135
Larsson (2022031300590168400_B5) 2006; 49
Farrow (2022031300590168400_B12) 1998; 7
Dehmer (2022031300590168400_B28) 2016; 164
Rothwell (2022031300590168400_B14) 2010; 376
McGlynn (2022031300590168400_B37) 2015; 107
Thun (2022031300590168400_B11) 1991; 325
Chen (2022031300590168400_B38) 2016; 138
2022031300590168400_B1
Nakamura (2022031300590168400_B2) 2017; 8
Bibbins-Domingo (2022031300590168400_B19) 2016; 164
Cole (2022031300590168400_B18) 2009; 101
Sasazuki (2022031300590168400_B32) 2013; 104
Rothwell (2022031300590168400_B16) 2012; 379
Giovannucci (2022031300590168400_B27) 2010; 33
Dale (2022031300590168400_B35) 2006; 295
Rydén (2022031300590168400_B40) 2013; 34
Larsson (2022031300590168400_B4) 2005; 97
Baigent (2022031300590168400_B25) 2009; 373
Dulai (2022031300590168400_B39) 2016; 355
Jacobs (2022031300590168400_B13) 2005; 97
Kasper (2022031300590168400_B33) 2006; 15
Bray (2022031300590168400_B29) 2017; 116
References_xml – volume: 8
  start-page: 397
  year: 2017
  ident: 2022031300590168400_B2
  article-title: Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: report of the Committee on Causes of Death in Diabetes Mellitus
  publication-title: J Diabetes Investig
  doi: 10.1111/jdi.12645
  contributor:
    fullname: Nakamura
– volume: 107
  year: 2015
  ident: 2022031300590168400_B37
  article-title: Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djv009
  contributor:
    fullname: McGlynn
– volume: 364
  start-page: 829
  year: 2011
  ident: 2022031300590168400_B10
  article-title: Diabetes mellitus, fasting glucose, and risk of cause-specific death
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1008862
  contributor:
    fullname: Rao Kondapally Seshasai
– volume: 159
  start-page: 77
  year: 2013
  ident: 2022031300590168400_B22
  article-title: Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-159-2-201307160-00002
  contributor:
    fullname: Cook
– volume: 97
  start-page: 1679
  year: 2005
  ident: 2022031300590168400_B4
  article-title: Diabetes mellitus and risk of colorectal cancer: a meta-analysis
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/dji375
  contributor:
    fullname: Larsson
– volume: 273
  start-page: 1605
  year: 1995
  ident: 2022031300590168400_B3
  article-title: Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis
  publication-title: JAMA
  doi: 10.1001/jama.1995.03520440059037
  contributor:
    fullname: Everhart
– volume: 67
  start-page: 10804
  year: 2007
  ident: 2022031300590168400_B34
  article-title: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-2310
  contributor:
    fullname: Dowling
– volume: 16
  start-page: 1103
  year: 2009
  ident: 2022031300590168400_B30
  article-title: Diabetes and cancer
  publication-title: Endocr Relat Cancer
  doi: 10.1677/ERC-09-0087
  contributor:
    fullname: Vigneri
– volume: 34
  start-page: 3035
  year: 2013
  ident: 2022031300590168400_B40
  article-title: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/eht108
  contributor:
    fullname: Rydén
– volume: 325
  start-page: 1593
  year: 1991
  ident: 2022031300590168400_B11
  article-title: Aspirin use and reduced risk of fatal colon cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199112053252301
  contributor:
    fullname: Thun
– ident: 2022031300590168400_B1
– volume: 164
  start-page: 777
  year: 2016
  ident: 2022031300590168400_B28
  article-title: Aspirin for the primary prevention of cardiovascular disease and colorectal cancer: a decision analysis for the U.S. Preventive Services Task Force
  publication-title: Ann Intern Med
  doi: 10.7326/M15-2129
  contributor:
    fullname: Dehmer
– volume: 376
  start-page: 1741
  year: 2010
  ident: 2022031300590168400_B14
  article-title: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)61543-7
  contributor:
    fullname: Rothwell
– volume: 116
  start-page: 27
  year: 2017
  ident: 2022031300590168400_B29
  article-title: Colorectal cancer screening
  publication-title: WMJ
  contributor:
    fullname: Bray
– volume: 4
  start-page: 81
  year: 2013
  ident: 2022031300590168400_B9
  article-title: Report of the JDS/JCA Joint Committee on Diabetes and Cancer
  publication-title: Diabetol Int
  doi: 10.1007/s13340-013-0121-3
  contributor:
    fullname: Kasuga
– volume: 377
  start-page: 31
  year: 2011
  ident: 2022031300590168400_B15
  article-title: Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)62110-1
  contributor:
    fullname: Rothwell
– volume: 97
  start-page: 975
  year: 2005
  ident: 2022031300590168400_B13
  article-title: A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/dji173
  contributor:
    fullname: Jacobs
– volume: 138
  start-page: 594
  year: 2016
  ident: 2022031300590168400_B38
  article-title: Statins and the risk of pancreatic cancer in type 2 diabetic patients--a population-based cohort study
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29813
  contributor:
    fullname: Chen
– volume: 7
  start-page: 97
  year: 1998
  ident: 2022031300590168400_B12
  article-title: Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer
  publication-title: Cancer Epidemiol Biomarkers Prev
  contributor:
    fullname: Farrow
– volume: 295
  start-page: 74
  year: 2006
  ident: 2022031300590168400_B35
  article-title: Statins and cancer risk: a meta-analysis
  publication-title: JAMA
  doi: 10.1001/jama.295.1.74
  contributor:
    fullname: Dale
– volume: 300
  start-page: 2134
  year: 2008
  ident: 2022031300590168400_B20
  article-title: Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial
  publication-title: JAMA
  doi: 10.1001/jama.2008.623
  contributor:
    fullname: Ogawa
– volume: 104
  start-page: 1499
  year: 2013
  ident: 2022031300590168400_B32
  article-title: Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan
  publication-title: Cancer Sci
  doi: 10.1111/cas.12241
  contributor:
    fullname: Sasazuki
– volume: 17
  start-page: 616
  year: 2011
  ident: 2022031300590168400_B7
  article-title: Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis
  publication-title: Endocr Pract
  doi: 10.4158/EP10357.RA
  contributor:
    fullname: Noto
– volume: 115
  start-page: 129
  year: 2016
  ident: 2022031300590168400_B24
  article-title: Statin use and all-cancer survival: prospective results from the Women’s Health Initiative
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2016.149
  contributor:
    fullname: Wang
– volume: 373
  start-page: 1849
  year: 2009
  ident: 2022031300590168400_B25
  article-title: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)60503-1
  contributor:
    fullname: Baigent
– volume: 355
  start-page: i6188
  year: 2016
  ident: 2022031300590168400_B39
  article-title: Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis
  publication-title: BMJ
  doi: 10.1136/bmj.i6188
  contributor:
    fullname: Dulai
– volume: 135
  start-page: 659
  year: 2017
  ident: 2022031300590168400_B21
  article-title: Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.116.025760
  contributor:
    fullname: Saito
– ident: 2022031300590168400_B31
– volume: 15
  start-page: 2056
  year: 2006
  ident: 2022031300590168400_B33
  article-title: A meta-analysis of diabetes mellitus and the risk of prostate cancer
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-06-0410
  contributor:
    fullname: Kasper
– volume: 44
  start-page: 2122
  year: 2008
  ident: 2022031300590168400_B36
  article-title: Statins and cancer: a systematic review and meta-analysis
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2008.06.025
  contributor:
    fullname: Kuoppala
– volume: 24
  start-page: 345
  year: 2010
  ident: 2022031300590168400_B8
  article-title: Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan
  publication-title: J Diabetes Complications
  doi: 10.1016/j.jdiacomp.2010.06.004
  contributor:
    fullname: Noto
– volume: 164
  start-page: 836
  year: 2016
  ident: 2022031300590168400_B19
  article-title: Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement
  publication-title: Ann Intern Med
  doi: 10.7326/M16-0577
  contributor:
    fullname: Bibbins-Domingo
– volume: 31
  start-page: 2391
  year: 2008
  ident: 2022031300590168400_B6
  article-title: Diabetes and risk of Non-Hodgkin’s lymphoma: a meta-analysis of observational studies
  publication-title: Diabetes Care
  doi: 10.2337/dc08-1034
  contributor:
    fullname: Mitri
– volume: 33
  start-page: 1674
  year: 2010
  ident: 2022031300590168400_B27
  article-title: Diabetes and cancer: a consensus report
  publication-title: Diabetes Care
  doi: 10.2337/dc10-0666
  contributor:
    fullname: Giovannucci
– volume: 49
  start-page: 2819
  year: 2006
  ident: 2022031300590168400_B5
  article-title: Diabetes mellitus and risk of bladder cancer: a meta-analysis
  publication-title: Diabetologia
  doi: 10.1007/s00125-006-0468-0
  contributor:
    fullname: Larsson
– volume: 33
  start-page: 1395
  year: 2010
  ident: 2022031300590168400_B26
  article-title: Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation
  publication-title: Diabetes Care
  doi: 10.2337/dc10-0555
  contributor:
    fullname: Pignone
– volume: 101
  start-page: 256
  year: 2009
  ident: 2022031300590168400_B18
  article-title: Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djn485
  contributor:
    fullname: Cole
– volume: 378
  start-page: 2081
  year: 2011
  ident: 2022031300590168400_B17
  article-title: Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)61049-0
  contributor:
    fullname: Burn
– volume: 27
  start-page: 2184
  year: 2016
  ident: 2022031300590168400_B23
  article-title: Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdw410
  contributor:
    fullname: Coyle
– volume: 379
  start-page: 1602
  year: 2012
  ident: 2022031300590168400_B16
  article-title: Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)61720-0
  contributor:
    fullname: Rothwell
SSID ssj0004488
Score 2.404643
Snippet This study analyzed the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes. This study was a posttrial follow-up of the Japanese...
OBJECTIVE This study analyzed the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes. RESEARCH DESIGN AND METHODS This study was...
OBJECTIVE This study analyzed the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes. RESEARCH DESIGN AND METHODS This study was...
OBJECTIVEThis study analyzed the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes.RESEARCH DESIGN AND METHODSThis study was a...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
StartPage 1757
SubjectTerms Adult
Aged
Aged, 80 and over
Arteriosclerosis
Aspirin
Aspirin - therapeutic use
Atherosclerosis
Cancer
Cardiovascular diseases
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - prevention & control
Chemoprevention - methods
Chemotherapy
Clinical trials
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - epidemiology
Evidence-based medicine
Female
Follow-Up Studies
Hemoglobin
Humans
Incidence
Japan - epidemiology
Male
Metformin
Metformin - therapeutic use
Middle Aged
Neoplasms - epidemiology
Neoplasms - prevention & control
Patients
Research design
Smoking
Statins
Subgroups
Title Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial
URI https://www.ncbi.nlm.nih.gov/pubmed/29909377
https://www.proquest.com/docview/2101339619/abstract/
https://search.proquest.com/docview/2056761017
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBAviO91G8gg3lBgTZzG5m0alDLYhiCI8hRdEgeismRqE03aPwJ_Lndx4qbTQMBLZMWt4_r3q313uQ_GngQow6pUIQIeqihUeNuBxHOdsVDgJ6BwC6Tg5MOj8fSTOJj5s8HgZ89rqa7iZ8n5pXEl_4Mq3kNcKUr2H5C1g-INbCO-eEWE8fpXGLeph0mYpBfmeUGm_33CcfGUMgFQhZOeP-MBHoxUcJLy8udNZNtnssKGxgrb-sY0LnK4a36hDD_HsTXaIpQT5Ex55tSnJqjyAxRpeZKfk43YOLx_x2ZIv7sv8nbjNkmwrU13DikYi3QKRbnILfDYRvY0BtwQ5nr5zXYdf4Wz5jvTfAmlNQ3BvD4BEwFQ9m0YI2k96Kpe2ADuZ3ZGF7nZGT-V4yu1tnubtFktS2VvK0a5KLjsjHC9JstAmtA0PFPTZz0P93TvY_T-5SR69-bo7RV21Q2UT2r969nKeQiVWmmcY82MTM4qGvq5HXhd0vmN-tKIMeFNdqPVP_ieIdMtNtDFbXbtsPWwuMN-GE7xMuMtp3hZcMMpfoFTHDs7TvGOU5w4xYlT3OXdSr_gLaP4GqO4ZRQ9D_iKUXzFKN4w6i4LJ6_C_anTFu9wEk_IysmyTCQACSrsqEMAiZqBRm3AF5kUmcIDOibvail0rIROcUEpSlpD5ksQo13vHtsoykJvMi6zZJTITAkqH5mCBBLqZSp1vKsRBm_IHnfrHJ2aFC0RqrYERkRgRATGkO10CETtP3gZuXgeeZ4aj9SQPbLduL_SSzNcvLLGz6CGEIzp4Bqy-wY5-xQS5VC8D7b-PPg2u74i_Q7bqBa1foCibBU_bFj1C4VWojs
link.rule.ids 315,786,790,27957,27958
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+Aspirin+on+Cancer+Chemoprevention+in+Japanese+Patients+With+Type+2+Diabetes%3A+10-Year+Observational+Follow-up+of+a+Randomized+Controlled+Trial&rft.jtitle=Diabetes+care&rft.au=Okada%2C+Sadanori&rft.au=Morimoto%2C+Takeshi&rft.au=Ogawa%2C+Hisao&rft.au=Sakuma%2C+Mio&rft.date=2018-08-01&rft.pub=American+Diabetes+Association&rft.issn=0149-5992&rft.volume=41&rft.issue=8&rft.spage=1757&rft_id=info:doi/10.2337%2Fdc18-0368&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0149-5992&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0149-5992&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0149-5992&client=summon